Detailed Information on Publication Record
2022
Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides
KOS, Jiří, Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY, Timotej JANKECH et. al.Basic information
Original name
Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides
Authors
KOS, Jiří (203 Czech Republic, guarantor, belonging to the institution), Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY (703 Slovakia, belonging to the institution), Timotej JANKECH, Tomáš GONĚC (203 Czech Republic, belonging to the institution), Pierre FRANCOTTE, Michel FREDERICH (203 Czech Republic) and Josef JAMPILEK (203 Czech Republic)
Edition
Molecules, Basel, MDPI, 2022, 1420-3049
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.600
RIV identification code
RIV/00216224:14110/22:00127693
Organization unit
Faculty of Medicine
UT WoS
000887320300001
Keywords in English
cinnamanilides; antiplasmodial activity; Plasmodium; structure-activity relationships
Tags
International impact, Reviewed
Změněno: 27/1/2023 10:52, Mgr. Tereza Miškechová
Abstract
V originále
Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.